S-1/A: Ceribell Unveils 2024 Incentive Award Plan Ahead of Potential IPO

Ceribell, Inc. introduces its 2024 Incentive Award Plan to attract, retain, and motivate key personnel through equity ownership opportunities.

Summary

• Ceribell, Inc. has established the 2024 Incentive Award Plan to attract, retain, and motivate individuals who contribute to the company.
• The plan allows for various types of awards, including stock options, stock appreciation rights, restricted stock, and cash-based awards.
• The overall share limit includes 4,366,326 shares, plus shares from prior plans that become available, and an annual increase of up to 5% of outstanding common stock from 2025-2034.
• A limit is set for non-employee director awards, not exceeding $750,000 in the first year and $500,000 in subsequent years.
• The plan includes provisions for adjustments in case of equity restructuring, corporate transactions, or a change in control.
• Awards are generally non-transferable, and the administrator has the discretion to amend or modify outstanding awards.
• The plan is governed by Delaware law and is intended to comply with Section 409A of the U.S. Internal Revenue Code.
• The plan was approved by the Board on October 2, 2024, and will become effective prior to the company's IPO, pending stockholder approval.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the company's growth, innovative technology, and market opportunity. However, it also acknowledges risks and uncertainties associated with the business and regulatory environment.

Positives

• The plan aims to enhance the company's ability to attract and retain key personnel.
• It offers a variety of award types to suit different employee needs and performance goals.
• The plan includes provisions for adjustments in case of corporate events, protecting award values.
• The plan is designed to comply with Section 409A of the Code, minimizing adverse tax consequences.

Negatives

• Awards are generally non-transferable, limiting flexibility for participants.
• The administrator has broad discretion to amend or modify awards, potentially affecting participant rights.
• The plan's effectiveness is contingent on stockholder approval and the completion of the company's IPO.

Risks

• The plan's success depends on the company's ability to manage and administer it effectively.
• External factors, such as changes in tax laws or accounting principles, could impact the plan's effectiveness.
• The plan's provisions may not adequately address the needs of all participants, potentially leading to dissatisfaction.
• The plan's reliance on administrator discretion could create uncertainty for participants.

Future Outlook

The company intends to leverage its proprietary database of EEG recordings and its data science and AI capabilities to expand the use of its system. The company believes that its system can be deployed with novel algorithms for various indications in the acute care setting. Thus, the company has begun the technical validation process for multiple additional indications, including the detection and monitoring of delirium, for which it received an FDA Breakthrough Device Designation in September 2022.

Industry Context

The announcement highlights Ceribell's focus on addressing the limitations of conventional EEG systems in the acute care setting. The company aims to become the standard of care for the detection and management of seizures in this environment, where delays in diagnosis and suboptimal patient care are common.

Comparison to Industry Standards

• Ceribell's primary competition is from conventional EEG systems, with key players being Natus and Nihon Kohden.
• These competitors have greater name and brand recognition, greater market share, greater resources, and may have larger sales forces than Ceribell.
• Ceribell also faces competition from companies that provide or are developing rapid EEG systems, including Nihon Kohden and a number of smaller companies.
• The company believes its Ceribell System has the ability to expand the use of EEG to a significantly broader set of acute care patients who should be monitored for non-convulsive seizures.
• The company estimates its total annual addressable market opportunity to be over $2 billion in the U.S. acute care setting.

Related Party Transactions

• Series C Redeemable Convertible Preferred Stock Financing
• Investors Rights Agreement
• Voting Agreement
• Right of First Refusal and Co-Sale Agreement
• Parvizi Consulting Agreement

Stakeholder Impact

• The Ceribell System aims to improve patient outcomes by enabling rapid diagnosis and treatment of seizures.
• Hospitals can benefit from cost savings and reduced strain on personnel through the use of the Ceribell System.
• Payers can also experience cost savings due to decreased hospital length of stay and reduced over-administration of medication.
• Employees are incentivized through the 2024 Incentive Award Plan, aligning their interests with the company's success.

Next Steps

• Increase adoption of the Ceribell System by new accounts.
• Drive utilization of the Ceribell System within our existing customer base.
• Continue to drive awareness of seizures in the acute care setting.
• Invest in further growing our base of clinical evidence.
• Continue to improve and innovate our system for use in seizures.
• Expand into new indications and clinical use cases beyond seizures.
• Pursue adjacent and international markets.

Key Dates

Keywords

Incentive Award Plan, Stock Options, Equity Compensation, Restricted Stock Units, Employee Benefits, CeriBell, IPO